Bifenpropathrin drops can cause a decrease in glutamate transaminase in about 1 week after the start of use, but the effect on serum aspartate transferase is weak. Bifenacoum can be used clinically for the treatment of acute and chronic viral hepatitis and drug-induced liver injury, which is caused by hepatitis, chemical toxicants or drugs. Generally, the use of about 1 week can make glutathione transaminase decreased, but the effect on serum aspartate transferase, glutamate transaminase and glutamate transpeptidase is weak. Also, bifenthix drops do not inhibit hepatitis virus replication or alter the pathology of hepatitis, but may only reduce the damage response of hepatitis virus. In addition, since bifenpropathrin only reduces transaminases alone, it needs to be combined with other medications, otherwise it will cause a resurgence of transaminases once the medication is discontinued. Therefore, patients are advised to visit the hepatology department of the hospital in time to use the medication under the guidance of the doctor if they are unwell.